 SOUTH SAN FRANCISCO, Calif., Oct. 14, 2021 GLOBE NEWSWIRE -- Aligos Therapeutics, Inc. Nasdaq: ALGS, a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced upcoming poster presentations highlighting data relating to its chronic hepatitis B CHB and nonalcoholic steatohepatitis NASH clinical programs at The Liver Meeting 2021, hosted by the American Association for the Study of Liver Diseases AASLD, being held virtually November 12 - 15, 2021. 